Can GlaxoSmithKline plc’s Share Price Return To 2,000p?

Will GlaxoSmithKline plc (LON: GSK) be able to return to its previous highs?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Right now I’m looking at some of the most popular companies in the FTSE 100 to try and establish whether or not they have the potential to return to historic highs. 

Today I’m looking at GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) to ascertain if its share price can return to 2,000p.

Initial catalyst

Of course, to establish whether or not the Glaxo’s share price will push back up to 2,000p, we need to establish what caused it to move there in the first place. In the case of Glaxo, it would appear that this rally was spurred by the merger of Glaxo with SmithKline Beecham back in 2001, forming the worlds largest pharmaceutical company.

Should you invest £1,000 in BHP right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if BHP made the list?

See the 6 stocks

What’s more, at this time the market was seemingly won over by the newly combined, GlaxoSmithKline’s future growth prospects. Indeed, investors were right to believe that the company was set for growth, as over the space of the next year, Glaxo’s pre-tax profit exploded 15% and earnings per share rose 10%.

Still, this growth was not enough to offset wider market consensus and unfortunately, just before Glaxo reached its high, the tech bubble had started to deflate. Over the next year-and-a-half, Glaxo’s share price declined a shocking 45%, roughly in line with similar declines reported for the FTSE 100.

But can Glaxo return to its former glory?

Sadly, Glaxo has been struggling during the past few years as it has lost the exclusive manufacturing rights to a number of its treatments and earnings have started to slide.

That said, it would appear that this is only reason that is standing in the way of the company’s return to greatness. Indeed, the company is already primed for a return to 2,000p per share, if it can increase margins and drive profits back to the levels seen during 2002.

Specifically, during 2002, Glaxo generated profits of £6.5 billion on revenues of £20.5 billion. However, during 2012, Glaxo reported revenues of £26.5 billion but profits of only £4.9 billion.

Of course, this depends on the development of the company’s treatment pipeline. Still, I have confidence in Glaxo’s ability to ride out this short-term slide in sales.

Actually, my figures suggest that if Glaxo does manage to drive profitability back to the level seen during 2002, the company is likely to be worth significantly more than 2,000p per share. In particular, during the past ten years, Glaxo has reduced its number of shares in issue by around 20%. This implies that if Glaxo’s profits hit £6.5 billion again, the company will earn 133p per share.

All in all, this implies that Glaxo will trade at a P/E of only 12.5 based on its current price. Moreover, it is likely that the market will place a premium on this kind of earnings growth.

Foolish summary

So, it would appear that Glaxo has all the foundations in place to make another run at 2,000p. The company just needs to cut costs further and inject some life into its treatment portfolio.

Overall, I feel that GlaxoSmithKline’s share price can return to 2,000p. 

Should you buy BHP shares today?

Before you decide, please take a moment to review this first.

Because my colleague Mark Rogers – The Motley Fool UK’s Director of Investing – has released this special report.

It’s called ‘5 Stocks for Trying to Build Wealth After 50’.

And it’s yours, free.

Of course, the decade ahead looks hazardous. What with inflation recently hitting 40-year highs, a ‘cost of living crisis’ and threat of a new Cold War, knowing where to invest has never been trickier.

And yet, despite the UK stock market recently hitting a new all-time high, Mark and his team think many shares still trade at a substantial discount, offering savvy investors plenty of potential opportunities to strike.

That’s why now could be an ideal time to secure this valuable investment research.

Mark’s ‘Foolish’ analysts have scoured the markets low and high.

This special report reveals 5 of his favourite long-term ‘Buys’.

Please, don’t make any big decisions before seeing them.

Claim your free copy now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Rupert does not own any share mentioned in this article. The Motley Fool has recommend shares in GlaxoSmithKline.

More on Investing Articles

Older couple walking in park
Investing Articles

Could £300 a month invested in US and UK shares reach a million by retirement?

Could an investor retire with a million pounds just by dedicating £300 a month to US and UK shares? Mark…

Read more »

Young Caucasian man making doubtful face at camera
Investing Articles

Is £800 enough to start an ISA?

Is it worth bothering with an ISA with less than £1,000 to spare? This writer believes it may be --…

Read more »

Investing Articles

3 reasons Tesla stock may be a long-term bargain

This writer is keen to buy Tesla stock at the right price. He doesn't think it's there yet -- but…

Read more »

Investing Articles

Nvidia stock is a lot cheaper than before – or is it?

Nvidia stock has been caught in the whirlwind of market volatility. This writer has been waiting to buy, so might…

Read more »

Top Stocks

3 FTSE stocks Fools are eyeing up for choppy markets

A selection of companies listed on the UK stock market on the watchlists of four Foolish investors.

Read more »

Young Black man sat in front of laptop while wearing headphones
Investing Articles

A £10,000 investment in Rolls-Royce shares last week is now worth this…

Harvey Jones says Rolls-Royce shares couldn't escape the volatility of recent weeks, but wonders if the recent dip is a…

Read more »

The flag of the United States of America flying in front of the Capitol building
Investing Articles

Prediction: in 2 years these S&P 500 stocks will be much higher than they are today

These two S&P 500 stocks have been beaten down in recent weeks. But Edward Sheldon expects them to move much…

Read more »

Investing Articles

10% yields! Why a volatile stock market is great news for passive income investors

The recent stock market volatility has given passive income investors the chance to earn double-digit returns. But they still need…

Read more »